Abstract
Neurotrophic tyrosine receptor kinase (
) fusion has been detected in rare types of CNS tumours, which can promote tumorigenesis. The efficacy of Trk inhibitor became a significant therapeutic interest. Our aim was to investigate whether Pan-Trk immunohistochemistry (IHC) is a reliable and efficient marker for detecting
fusion in different brain tumours.
This study included 23 patients diagnosed with different types of CNS tumours. Testing for Pan-Trk IHC with monoclonal Ab (EPR17341) has been performed on all FFPE tissues. Parallelly,
-rearrangements were tested using both DNA and RNA-based next-generation sequencing (NGS) assay using TruSight Onco500 platform.
The cohort included eight pilocytic astrocytomas, one oligodendroglioma, six IDH
glioblastomas, four IDH
grade four astrocytomas, and one sample of each (astroblastoma, central neurocytoma, medulloblastoma, and liponeurocytoma). The mean age was 35 years; seven cases were in the paediatric age group, and 16 were adult. Pan-Trk expression was detected in 11 (47.8%) tumours, and 12 (52.1%) tumours showed no Pan-Trk expression. Nine Cases (82%) with different Pan-Trk expressions did not reveal
-rearrangement. The other two positively expressed cases (liponeurocytoma and glioblastoma) were found to have
-fusions (
). All the 12 cases (100%) with no Pan-Trk expression have shown no
-fusions. There was no statistically significant association between Pan-Trk expression and
-fusion (
= 0.217). The detection of
fusions using NGS had high specificity over
-fusion detection by using Pan-Trk IHC.
Pan-Trk IHC is not a suitable tissue-efficient biomarker to screen for
-fusions in CNS tumours, however RNA-based NGS sequencing should be used as an alternative method.